NCT04045262 is a clinical trial in Critical Illness, sponsored by Fernando Suarez Sipmann.

Who is sponsoring NCT04045262?

NCT04045262 is sponsored by Fernando Suarez Sipmann.

What condition does NCT04045262 study?

NCT04045262 studies Critical Illness.

Is NCT04045262 still recruiting?

NCT04045262 is currently completed. Last updated 12 October 2022.

Last reviewed 2022-10-12 · How we verify

NCT04045262

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Validation of Continuous and Non-invasive Monitoring of Effective Pulmonary Volume.

Completed Last updated 12 October 2022

What this trial tests

trial in Critical Illness in 85 participants. Completed in 30 March 2022.

Timeline

4 June 2019

Primary endpoint
30 March 2022

30 March 2022

Quick facts

Lead sponsor	Fernando Suarez Sipmann
Status	Completed
Study type	OBSERVATIONAL
Enrollment	85
Start date	4 June 2019
Primary completion	30 March 2022
Estimated completion	30 March 2022
Sites	1 location across Spain

Conditions studied

Critical Illness — all drugs for Critical Illness →

Sponsor

Fernando Suarez Sipmann

Who can join

18 and older, any sex, with Critical Illness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate/validate a new non-invasive method to continuously monitor effective lung volume in critically ill patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Clinical validation of a capnodynamic method for measuring end-expiratory lung volume in critically ill patients.
Sanchez Giralt JA, Tusman G, Wallin M, Hallback M, et al · · 2024 · cited 2× · PMID 38689313 · DOI 10.1186/s13054-024-04928-w

Verify or expand the search:

Other recruiting trials for Critical Illness

Currently open trials in the same condition.

NCT06189924 — Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients · recruiting
NCT07418242 — Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients · recruiting
NCT07101640 — PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysp · Phase 1, PHASE2 · recruiting
NCT07177183 — Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure · NA · recruiting
NCT07369258 — Clinical Application of Listening to Music to Prevent Delirium in the Intensive Care Unit · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04045262 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fernando Suarez Sipmann
Last refreshed: 12 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04045262.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing